Skip to main content

Table 4 Rankings of mean response at week 24 by treatment group

From: Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study

Assessment Group 1 [1 × 6 mL (N = 20)] Group 2 [1 × 4 mL (N = 21)] Group 3 [2 × 4 mL (N = 19)] Group 4 [3 × 4 mL (N = 20)] Group 5 [3 × 2 mL (N = 20)]
Patient knee OA Pain 2 4 5 3 1
WOMAC A 2 5 4 1 3
WOMAC B 4 5 3 2 1
WOMAC C 2 4 5 1 3
Patient global assessment 1 5 4 2 3
Physician global assessment 1 5 4 3 2
Total 2 5 4 1 3